Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ADYNOVI for the Treatment of Adults and Adolescents with Haemophilia A

Drug Name

ADYNOVI® (anti-haemophilic factor (recombinant), PEGylated)

Developer

Shire

Therapy Class

Recombinant anti-haemophilic factor (blood coagulation factor VIII)

Current Indication

Haemophilia A

Market Sector

Genetics

Development Status

Approved in the US and Europe
Expand

Go Top